Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04430738
Title	Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Recruitment	Active, not recruiting
Gender	both
Phase	Phase Ib/II
Variant Requirements	No
Sponsors	Seagen Inc.
Indications	colorectal cancer gastric adenocarcinoma gallbladder carcinoma cholangiocarcinoma esophagus adenocarcinoma gastroesophageal junction adenocarcinoma
Therapies	Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib
Age Groups:	adult \| senior
Covered Countries	USA